Global impact of the COVID‐19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries
Authors: Vigliar Elena , Cepurnaite Rima , Alcaraz‐Mateos Eduardo , Ali Syed Z. , Baloch Zubair W. , Bellevicine Claudio , Bongiovanni Massimo , Botsun Pavlina , Bruzzese Dario , Bubendorf Lukas , Büttner Reinhard , Canberk Sule , Capitanio Arrigo , Casadio Chiara , Cazacu Eugeniu , Cochand‐Priollet Beatrix , D’Amuri Alessandro , Eloy Catarina , Engels Marianne , Fadda Guido , Fontanini Gabriella , Fulciniti Franco , Hofman Paul , Iaccarino Antonino , Ieni Antonio , Jiang Xiaoyin Sara , Kakudo Kennichi , Kern Izidor , Kholova Ivana , Liu Chinhua , Lobo Anandi , Lozano Maria D. , Malapelle Umberto , Maleki Zahra , Michelow Pamela , Musayev Jamal , Özgün Gonca , Oznur Meltem , Peiró Marqués Francisca Maria , Pisapia Pasquale , Poller David , Pyzlak Michal , Robinson Betsy , Rossi Esther Diana , Roy‐Chowdhuri Sinchita , Saieg Mauro , Savic Prince Spasenija , Schmitt Fernando C. , Javier Seguí Iváñez Francisco , Štoos‐Veić Tajana , Sulaieva Oksana , Sweeney Brenda J. , Tuccari Giovanni , van Velthuysen Marie‐Louise , VanderLaan Paul A. , Vielh Philippe , Viola Patrizia , Voorham Rinus , Weynand Birgit , Zeppa Pio , Faquin William C. , Pitman Martha Bishop , Troncone Giancarlo 
Published: October 2020

BackgroundTo the authors' knowledge, the impact of the coronavirus disease 2019 (COVID‐19) pandemic on cytopathology practices worldwide has not been investigated formally. In the current study, data from 41 respondents from 23 countries were reported.MethodsData regarding the activity of each cytopathology laboratory during 4 weeks of COVID‐19 lockdown were collected and compared with those obtained during the corresponding period in 2019. The overall number and percentage of exfoliative and fine‐needle aspiration cytology samples from each anatomic site were recorded. Differences in the malignancy and suspicious rates between the 2 periods were analyzed using a meta‐analytical approach.ResultsOverall, the sample volume was lower compared with 2019 (104,319 samples vs 190,225 samples), with an average volume reduction of 45.3% (range, 0.1%‐98.0%). The percentage of samples from the cervicovaginal tract, thyroid, and anorectal region was significantly reduced (P < .05). Conversely, the percentage of samples from the urinary tract, serous cavities, breast, lymph nodes, respiratory tract, salivary glands, central nervous system, gastrointestinal tract, pancreas, liver, and biliary tract increased (P < .05). An overall increase of 5.56% (95% CI, 3.77%‐7.35%) in the malignancy rate in nongynecological samples during the COVID‐19 pandemic was observed. When the suspicious category was included, the overall increase was 6.95% (95% CI, 4.63%‐9.27%).ConclusionsThe COVID‐19 pandemic resulted in a drastic reduction in the total number of cytology specimens regardless of anatomic site or specimen type. The rate of malignancy increased, reflecting the prioritization of patients with cancer who were considered to be at high risk. Prospective monitoring of the effect of delays in access to health services during the lockdown period is warranted.